Brief: NFL Biosciences Launches Phase 2/3 Clinical Trial For Smoking Cessation

Nfl Biosciences SAS

14/12/2021 16:48

Dec 14 (Reuters) - Nfl Biosciences SAS  ALNFL.PA :
    * REG-NFL BIOSCIENCES: PHASE II/III CLINICAL TRIAL LAUNCHED
FOR
SMOKING CESSATION
    * INCLUSION OF PATIENTS FROM JANUARY 2022
    * LAUNCHING ITS CESTO II PHASE II/III CLINICAL TRIAL TO
ASSESS
EFFICACY AND SAFETY OF ITS NFL-101 SMOKING CESSATION TREATMENT

Source text for Eikon:  ID:nGNE6Jf8Qk 
Further company coverage:  ALNFL.PA 

 (Paris Newsroom)